Ken Paulus is stepping down from his position as President and CEO of Prime Therapeutics LLC, a pharmacy benefit manager (PBM) serving nearly 38 million members nationally. Mostafa Kamal will take his place, taking on the mantle of leading the organization as President and CEO. As Prime embarks on this new era of leadership, the company is poised to accelerate growth as it continues to deliver on its promise to offer quality, cost-effective health care options to its members.
Mostafa Kamal is set to become the next leader of Prime Therapeutics and its subsidiary, Magellan Rx. This exciting new position will provide an opportunity for Kamal to shape the future of pharmacy benefit management. Maurice Smith, Prime’s Board Chairman and President, CEO and Vice Chair of Health Care Service Corporation, said of Kamal’s vision, “it’s inspiring and bold.” Smith continued, “As Prime seeks to reimagine pharmacy benefit management, Mostafa is the perfect person to take the company forward following the retirement of Ken.”
Mostafa Kamal has been appointed to lead Prime Health, and succeeds Paulus who has been at the helm for the past four years. As Kamal takes the reins of the newly combined organization, he is filled with pride and honor as he is keenly aware of the impact it will have on patient lives.
With the right solutions, scale and know-how, the organization is set to be a powerful player in the healthcare industry. Paulus, on the other hand, is confident that the team will continue to excel in providing the best care under Kamal’s leadership.
Kamal played a pivotal role in crafting the 2022 agreement that united Prime and Magellan Rx and catapulted them into a new era of healthcare solutions. As CEO of Magellan Rx, Kamal steered the company through a period of substantial growth and development, transforming it into a major force in the pharmacy benefit management industry.
Along the way, Magellan Rx established itself as an industry leader in specialty drug management, state government pharmacy solutions, and middle market PBM solutions, all while promoting better access and quality to improve the health and wellbeing of members and patients across the country.
Kamal Subramanyam is the CEO of Magellan Rx, a leader in specialty pharmacy services. With a Bachelor of Science degree in Economics from Rutgers University, Kamal has a long history of experience in the healthcare industry. After a lengthy tenure with Medco Health Solutions (now Express Scripts), Kamal rose to become the Chief Underwriting Officer for Magellan Rx, overseeing pricing, analytics and risk management strategies. His achievements have enabled him to take over the reins as esteemed CEO, providing clients with enhanced financial solutions to help manage their pharmacy spend.
About Prime Therapeutics + Magellan Rx
Prime Therapeutics LLC is a cutting-edge pharmacy solutions organization that connects health plans, employers, and government programs with comprehensive services. Our collective 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates ensure reliable results.
Magellan Rx Management, a Prime Therapeutics LLC Company, paves the way with expertise in specialty and medical drug management, leading the way for public sector state government programs. We bridge the gap between medical and pharmacy management, delivering cost-effective solutions to our ever-expanding client base.